Creation of a research partnership between Pierre Fabre and Y-... - 23 November 2020 09:00

DAEJEON, South Korea and CASTRES, France, Nov. 23, 2020 /PRNewswire-AsiaNet/-- The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have announced their plans to form a strategic partnership in the field of immuno-oncology research. The decision has been acknowledged through a letter ...

  RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First... - 21 November 2020 00:20

TEL AVIV, Israel and RALEIGH, N.C., November 20, 2020, /PRNewswire-AsiaNet/-- RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease - a rare condition with no FDA-approved first-line therapy The Phase 3 study is expected to recruit up to 125 patien...

  INOVIO Presents Clinical Results of its DNA Medicines INO-5401... - 21 November 2020 00:00

PLYMOUTH MEETING, Pennsylvania Nov. 20, 2020 /PRNewswire-AsiaNet/ -- -- Interim review in newly diagnosed glioblastoma patients provides OS18 data, demonstrates immunogenicity and tolerability in a majority of patients INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely...

  Leading Indian CRO-CDMO, Sai Life Sciences opens representativ... - 20 November 2020 11:00

TOKYO and HYDERABAD, India, Nov. 17 /PRNewswire-AsiaNet/-- - Participating in the PharmaLab Expo Tokyo during Nov 25-27 to jumpstart outreach Sai Life Sciences, one of India's fastest growing Contract Research, Development & Manufacturing Organizations [https://www.sailife.com/?utm_source=pr&utm_me...

  RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleare... - 20 November 2020 09:00

TEL AVIV, Israel and RALEIGH, N.C., Nov. 17, 2020 /PRNewswire-AsiaNet/ -- FDA clears IND application for Phase 2/3 study with RedHill's second novel COVID-19 candidate, RHB-107 (upamostat), an orally administered novel serine protease inhibitor, with demonstrated antiviral and potential tissue-protective effects The ...

  RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase... - 20 November 2020 09:00

TEL AVIV, Israel and RALEIGH, NC, Nov. 20, 2020 /PRNewswire-AsiaNet/ -- Enrollment completed in the U.S. Phase 2 study evaluating opaganib's safety and initial efficacy signal in 40 hospitalized patients with severe COVID-19 pneumonia A parallel global Phase 2/3 study with orally administered opaganib for severe CO...

  MIM Software Inc. Announces Collaboration with Peter MacCallum... - 20 November 2020 03:53

CLEVELAND, Nov. 20, 2020 /PRNewswire-AsiaNet/ -- MIM Software Inc., a leading global provider of medical imaging software, announced today a collaboration with Peter MacCallum Cancer Centre (Peter Mac) in support of its Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) prog...

  LimaCorporate Announces FDA Approval for an Ide Study on Smr S... - 20 November 2020 02:00

UDINE, Italy, Nov. 20, 2020 /PRNewswire-AsiaNet/ -- LimaCorporate is proud to announce that the U.S. Food and Drug Administration (FDA) has approved the Investigational Device Exemption (IDE) to start the clinical trial of the SMR Stemless Reverse Shoulder System. Logo - https://mma.prnewswire.c...

  endpoint and McCreadie Group Software Integration Reduces Drug... - 20 November 2020 01:00

SAN FRANCISCO and ANN ARBOR, Mich., Nov. 19, 2020 /PRNewswire-AsiaNet/ -- endpoint Clinical ( https://c212.net/c/link/?t=0&l=en&o=2986884-1&h=3561717008&u=https%3A%2F%2Fwww.endpointclinical.com%2Firt-solution%2F&a=endpoint+Clinical ), the leading global interactive response technology (IRT(R)) company, and McCreadie Gro...

  RedHill Announces Unanimous DSMB Recommendation to Continue Ph... - 19 November 2020 23:59

TEL AVIV, Israel and RALEIGH, N.C., Nov. 23, 2020, /PRNewswire-AsiaNet/-- Pre-scheduled independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia Enrollment in the 270-patient global Phase 2/3 COV...